Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Inhibikase Therapeutics Inc banner

Inhibikase Therapeutics Inc
NASDAQ:IKT

Watchlist Manager
Inhibikase Therapeutics Inc Logo
Inhibikase Therapeutics Inc
NASDAQ:IKT
Watchlist
Price: 1.58 USD 1.28% Market Closed
Market Cap: $191.6m
Write Note Create Alert Ask AI

Profitability Summary

Inhibikase Therapeutics Inc's profitability score is 12/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

12/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

12/100
Profitability
Score
12/100
Profitability
Score

Margins

Earnings Waterfall
Inhibikase Therapeutics Inc

Margins Comparison
Inhibikase Therapeutics Inc Competitors

Country Company Market Cap Operating
Margin 		Net
Margin
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
191.6m USD
Loading...
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
Loading...
US
Abbvie Inc
NYSE:ABBV
395.1B USD
Loading...
Loading...
US
Amgen Inc
NASDAQ:AMGN
204.9B USD
Loading...
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
190B USD
Loading...
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.3B USD
Loading...
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
Loading...
Loading...
AU
CSL Ltd
ASX:CSL
87.4B AUD
Loading...
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...
Loading...

Return on Capital

Return on Capital Comparison
Inhibikase Therapeutics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
191.6m USD
Loading...
Loading...
Loading...
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
Loading...
Loading...
Loading...
US
Abbvie Inc
NYSE:ABBV
395.1B USD
Loading...
Loading...
Loading...
Loading...
US
Amgen Inc
NASDAQ:AMGN
204.9B USD
Loading...
Loading...
Loading...
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
190B USD
Loading...
Loading...
Loading...
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.3B USD
Loading...
Loading...
Loading...
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
Loading...
Loading...
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
Loading...
Loading...
Loading...
Loading...
AU
CSL Ltd
ASX:CSL
87.4B AUD
Loading...
Loading...
Loading...
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
Loading...
Loading...
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...
Loading...
Loading...
Loading...

Free Cash Flow

Free Cash Flow Analysis
Inhibikase Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

See Also

Summary
IKT intrinsic value, competitors valuation, and company profile.
DCF Valuation
IKT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IKT stock valuation using valuation multiples.
Wall Street Estimates
IKT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IKT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 315,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.